StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Equities research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Down 9.1 %

Shares of TRVN stock opened at $1.69 on Wednesday. Trevena has a 12-month low of $1.13 and a 12-month high of $17.51. The firm has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $3.17. The company has a market capitalization of $1.45 million, a PE ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million during the quarter. As a group, research analysts expect that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.